San Diego, United States
Fate Therapeutics Inc., founded in 2007 and headquartered in the United States, is a clinical-stage biopharmaceutical leader with a compelling mission of "Transforming the lives of patients with autoimmune diseases and cancer."
The company excels in the Biotechnology sector, offering innovative induced pluripotent stem cell (iPSC)-derived cellular immunotherapies. With its proprietary iPSC product platform, Fate Therapeutics has established itself at the forefront of creating multiplexed-engineered master iPSC lines, focusing on off-the-shelf products.
Its robust pipeline is notable for its iPSC-derived T-cell and natural killer (NK) cell candidates, engineered to incorporate novel synthetic controls for enhanced therapeutic utility. This positions Fate Therapeutics to address unmet medical needs in immunotherapy by delivering versatile treatment mechanisms.
On March 1, 2024, the company secured a substantial $100.00M investment through a private placement, attracting prestigious investors like OrbiMed, Boxer Capital, Adage Capital Management, Deep Track Capital, and Suvretta Capital Management, underscoring strong investor confidence in its strategic vision and innovation.
